牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-01-04 AccNo: 0001535610-19-000020 Size: 15 KB 网页链接
$灿菲特生物制药(CANF)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-01-03 AccNo: 0001178913-19-000024 Size: 87 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-12-10 AccNo: 0001213900-18-017150 Size: 16 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-12-10 AccNo: 0001213900-18-017108 Size: 31 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-12-03 AccNo: 0001213900-18-016845 Size: 10 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-11-30 AccNo: 0001213900-18-016751 Size: 95 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-11-20 AccNo: 0001213900-18-016255 Size: 26 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-10-31 AccNo: 0001213900-18-014707 Size: 34 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-10-31 AccNo: 0001213900-18-014707 Size: 34 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-10-25 AccNo: 0001213900-18-014466 Size: 553 KB 网页链接